TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06784362

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study
Study: NCT06787534

Intervention type: OTHER
Intervention: No Interventions

Intervention type: OTHER
Intervention: No Interventions
Study: NCT06785896

Intervention type: PROCEDURE
Intervention: Angle Class II unilateral, treated by carriere motion appliance
Description: This treatment was unilateral, with dental composite bites ramps behind canines
Study: NCT00639106

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Without ALLODERM, Questionnaires
Description: A standard, sub-muscular pocket dissection will be performed in the patients assigned to the control group. No Alloderm will be used.
Study: NCT03453957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Professional development program
Description: Professional development program consists of training including workshops and consultation sessions to enhance therapists ability to detect and repair alliance ruptures in active community based psychotherapy.
Study: NCT03934918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Patients for IOL are sent home after placement of intracervical balloon
Study: NCT03059537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral chenodeoxycholic acid stimulation
Description: oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor
Study: NCT02830074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best practices PAP + patient Education +ongoing Support and Training
Description: This is a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + Education + ongoing Support/Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: This program includes non-directive sleep education plus standard treatment of SDB.
Study: NCT01834664

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: stem cell (MNCs )
Description: Intra thecal transplantation of autologous stem cell \[MNCs \]Per dose at the interval
Study: NCT05514613

Intervention type: OTHER
Intervention: retrospektif study; The effect of tracheostomy tecnique method on complications
Description: retrospektif study; The effect of tracheostomy tecnique method on complications complications and correlation of complications with techniques

Intervention type: OTHER
Intervention: retrospektif study; The effect of tracheostomy tecnique method on complications
Description: retrospektif study; The effect of tracheostomy tecnique method on complications complications and correlation of complications with techniques
Study: NCT03778060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cala TWO stimulator
Description: Treatment intervention will consist of subjects undergoing 40 minute sessions of transcutaneous stimulation with the Cala TWO stimulator twice daily for 3 months to reduce hand tremors prior to their undergoing deep brain stimulation 'surgery for treatment of essential tremor at Mayo Clinic.
Study: NCT03231397

Intervention type: DRUG
Group type: OTHER
Intervention: Assess AAA rupture risk by PET-CTA scans
Description: Assess AAA rupture risk by PET-CTA scans

Intervention type: DRUG
Group type: OTHER
Intervention: Assess AAA rupture risk by PET-CTA scans
Description: Assess AAA rupture risk by PET-CTA scans

Intervention type: DRUG
Group type: OTHER
Intervention: Assess AAA rupture risk by PET-CTA scans
Description: Assess AAA rupture risk by PET-CTA scans

Intervention type: DRUG
Group type: OTHER
Intervention: Assess AAA rupture risk by PET-CTA scans
Description: Assess AAA rupture risk by PET-CTA scans

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-fludeoxyglucose (FDG)
Description: Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-fludeoxyglucose (FDG)
Description: Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-fludeoxyglucose (FDG)
Description: Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-fludeoxyglucose (FDG)
Description: Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 11C-PBR28
Description: Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 11C-PBR28
Description: Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 11C-PBR28
Description: Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 11C-PBR28
Description: Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
Study: NCT02843165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Checkpoint blockade immunotherapy
Description: Approved Checkpoint blockade immunotherapy (including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Checkpoint blockade immunotherapy plus SBRT
Description: SBRT at 28.5 Gy (9.5 Gy x3 fractions) will be delivered within 1 - 21 days of the start of Cycle 1 of the CBI plus CBI (approved CBIs including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
Study: NCT02758288

Intervention type: OTHER
Intervention: New Protocol - BK viremia or BK virus nephropathy
Description: Data collected prospectively that will follow new clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.

Intervention type: OTHER
Intervention: Standard Protocol - BK viremia or BK virus nephropathy
Description: Data collected retrospectively that followed standard clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
Study: NCT01641471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMPI Select TENS
Description: The unit is capable of 0-60 milliamps of output current.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo EMPI Select TENS
Description: The sham unit appears identical to the Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation.
Study: NCT01183507

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NIA intervention
Description: The NIA physical activity intervention is of moderate intensity and will consist of aerobic, strength, flexibility, and balance training, with a target duration of 120 minutes per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TSE
Description: The TSE intervention is also of moderate intensity and target duration of 120 minutes per week and will consist of exercises that closely mimic functional tasks, such as vacuuming, stair ascent and descent, and lifting a weighted laundry basket.
Study: NCT03993977

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rotational thromboelastometry
Description: ROTEM-guided protocol of hemostatic resuscitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Clinical judgement and conventional coagulation tests
Study: NCT02685332

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation
Description: Stereotactic Body Partial Breast irradiation Step No. Fractions Dose per fraction~-1 1 20 0 (starting) 1 22.5~1. 1 26.5~2. 1 30
Study: NCT04099238

Intervention type: DRUG
Intervention: Oral anticoagulant
Description: Oral anticoagulants may comprise vitamin K antagonists (VKA) and non-vitamin K antagonist oral antagonists (NOAC).

Intervention type: DRUG
Intervention: Oral anticoagulant
Description: Oral anticoagulants may comprise vitamin K antagonists (VKA) and non-vitamin K antagonist oral antagonists (NOAC).
Study: NCT04929977

Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable device with smart mobile phone
Description: The wearable device will act as a sensor designed to identify critical parameters such as Kangaroo Mother Care adherence and temperature of the infant 24/7 and of the mother-infant pairs during these sessions.
Study: NCT01383408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exhalation analysis of breath sample
Description: study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: exhalation analysis of breath sample
Description: study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exhalation analysis of breath sample
Description: study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exhalation analysis of breath sample
Description: study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis
Study: NCT00765817

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, twice a day, 10mcg
Study: NCT00528918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glulisine (Apidra)
Description: An algorithm to determine the initial doses of insulin and dose adjustments is as follows: Lean subjects (BMI less than 25 kg/m2) will initially receive a total of 0.4 units/kg/day, overweight subjects (BMI 25-30 kg/m2) 0.5 units/kg/day and obese subjects (BMI greater than 30 kg/m2) 0.6 units/kg/day. Fifty percent of the total amount of insulin will be given as Glargine and 50% as regular insulin or Apidra. Supplemental short-acting insulin will be given for hyperglycemia before meals. Automated order sets shall be generated to minimize errors in order entries. Glucose concentrations will be measured before each meal and at bedtime, and if symptomatic. In addition, eight-point blood glucose profiles will be obtained every three days starting on day 2. Dose adjustments will be made to keep blood glucose concentrations between 80 and 120 mg/dl pre-prandially and less than180 mg/dl after meals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glulisine (Apidra)
Description: An algorithm to determine the initial doses of insulin and dose adjustments is as follows: Lean subjects (BMI less than 25 kg/m2) will initially receive a total of 0.4 units/kg/day, overweight subjects (BMI 25-30 kg/m2) 0.5 units/kg/day and obese subjects (BMI greater than 30 kg/m2) 0.6 units/kg/day. Fifty percent of the total amount of insulin will be given as Glargine and 50% as regular insulin or Apidra. Supplemental short-acting insulin will be given for hyperglycemia before meals. Automated order sets shall be generated to minimize errors in order entries. Glucose concentrations will be measured before each meal and at bedtime, and if symptomatic. In addition, eight-point blood glucose profiles will be obtained every three days starting on day 2. Dose adjustments will be made to keep blood glucose concentrations between 80 and 120 mg/dl pre-prandially and less than180 mg/dl after meals.
Study: NCT03243123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic passive mobilization
Description: The intervention was performed using the Gloreha (Idrogenet, Italy) robotic system. The system consists of a soft exoskeleton similar to a glove. Passive hand joints mobilization is provided by a hydraulic system. Each patient underwent a session of 20 min passive mobilization of the paretic hand.
Study: NCT02482545

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal replacement
Study: NCT00812942

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy
Description: colonoscopy screening

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: faecal test
Description: faecal occult blood test for screening
Study: NCT02085928

Intervention type: OTHER
Intervention: Intratissue percutaneous electrolysis, associated with eccentric exercise and stretching
Description: * The EPI technique was performed under ultrasound-guidance on the clinically relevant area (or areas of maximum tenderness to palpation and with ultrasonographic degenerative tendon changes) using an intensity of 4-6 mA during 3 seconds, approximately 3 times. We used the EPI machine (Cesmar Electromedicina S.L., Barcelona, Spain) and a GE Logiq E Portable Ultrasound Machine with GE Linear probe 12L-RS (5-13 mhz) (GE Healthcare, Wisconsin, EEUU).~* The eccentric exercise program consisted of three series of up to 10 repetitions of eccentric work, repeated twice daily (morning and afternoon), under maximum load (initially with one kilogram) in an optimal and functional pain-free range.~* The stretching program consisted of a stretching exercise for the epicondylar muscles consisting in three series of 7 repetitions twice a day (morning and afternoon.
Study: NCT03479476

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Medication
Description: Placebo liquid or capsules given in parallel to active medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Active medication.
Study: NCT04007666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD that combines education about trauma with strategies to challenge the trauma-related cognitions that are theorized to maintain PTSD symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Coping-focused treatment.
Study: NCT02552017

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff Vision
Description: Endocuff Vision is a new device made of soft plastic material with a unique dynamic shape. It is manufactured by ARC Medical Design Limited and Diagmed in the United Kingdom. It has European Conformity in United Kingdom. The core is made of polypropylene and the 'finger like' projections are made of a thermoplastic elastomer. It comes in four colour coded sizes (purple, blue, green and orange) to fit a range of paediatric and adult colonoscopes. Endocuff Vision is the more updated version of device that has only one proximal row of more rounded finger-like projections. It is mounted at the tip of the colonoscope and held on by friction (pull-off force is a minimum of 10 Newtons).
Study: NCT01986088

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Description: 40mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Description: 80mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Description: 50mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Description: 100mg oral
Study: NCT00527787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400 (VIMOVO)
Description: PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen (500 mg) dosed twice daily (bid) orally
Study: NCT02700542

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Integrated Pest Management
Description: One-time, in-home, pest intervention for children with persistent asthma living in homes with parent-reported cockroach and/or mouse infestation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Pest Management
Description: One-time, in-home, pest intervention for children with persistent asthma living in homes with parent-reported cockroach and/or mouse infestation.
Study: NCT02986308

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT02878694

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myoblast autologous graft
Description: 30 million autologous myoblasts in 6 intramuscular injections No treatment in the second eye
Study: NCT03750929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined acute physical exercises (strength and aerobic)
Description: Patients will be submmitted to combined acute physical exercises (strength and aerobic)
Study: NCT03973268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm 1, 2, 3 device interventions
Description: MagPro 100 TMS Therapy System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm 1, 2, 3 device interventions
Description: MagPro 100 TMS Therapy System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm 1, 2, 3 device interventions
Description: MagPro 100 TMS Therapy System

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 2 Interventions
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1, 2, 3 drug Interventions
Description: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1, 2, 3 drug Interventions
Description: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1 and 2 Interventions
Description: Perampanel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1 and 2 Interventions
Description: Perampanel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1 and 2 Interventions
Description: Perampanel
Study: NCT04621253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novalgin
Description: Single dose of 1000 mg metamizole, 1h after the last inhibitor or placebo intake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novalgin
Description: Single dose of 1000 mg metamizole, 1h after the last inhibitor or placebo intake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Novalgin
Description: Single dose of 1000 mg metamizole, 1h after the last inhibitor or placebo intake
Study: NCT03040934

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Firehawk sirolimus target eluting coronary stent system
Description: 98 subjects will be enrolled to receive a test device of Firehawk sirolimus target eluting coronary stent system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE Everolimus-Eluting Coronary Stent System
Description: 98 subjects will be enrolled to receive a control device of XIENCE Everolimus-Eluting Coronary Stent System
Study: NCT00903500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily physical activity, pedometer and counseling
Description: Individual counseling session, telephone counseling (7 calls), given by a psychologist and a pedometer, based on cognitive behavioral therapy, the Diabetes Prevention Program, the first Step Program and Motivational Interviewing
Study: NCT03916796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: -The exercise part will consist of an evaluation and treatment as prescribed by a physical therapist including aerobic \& dynamic stretching warm-up, strength training, balance training, and flexibility training. Will also include a home exercise program (HEP). Physical therapists will have specialized training in cancer rehabilitation obtained through the ReVital certification process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: -The exercise part will consist of an evaluation and treatment as prescribed by a physical therapist including aerobic \& dynamic stretching warm-up, strength training, balance training, and flexibility training. Will also include a home exercise program (HEP). Physical therapists will have specialized training in cancer rehabilitation obtained through the ReVital certification process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery after surgery
Description: -The protocols include instructions for patient care from the time of pre-surgical admission to discharge, including directives regarding diet, labs, IV fluids, pain management, prophylactic medications, management of indwelling catheters and drains, and activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery after surgery
Description: -The protocols include instructions for patient care from the time of pre-surgical admission to discharge, including directives regarding diet, labs, IV fluids, pain management, prophylactic medications, management of indwelling catheters and drains, and activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological screening with counselling services as needed
Description: -The psychological screening will be completed by the Radiation Oncology nurse at the consult visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological screening with counselling services as needed
Description: -The psychological screening will be completed by the Radiation Oncology nurse at the consult visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Counseling Services
Description: -Patients will have a baseline nutrition counseling visit with a Registered Dietician. This may include a nutrition assessment and nutrition counseling to set priorities, establish goals, and create an individualized plan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Counseling Services
Description: -Patients will have a baseline nutrition counseling visit with a Registered Dietician. This may include a nutrition assessment and nutrition counseling to set priorities, establish goals, and create an individualized plan
Study: NCT01603888

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention
Study: NCT01795599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifegyne ®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifegyne ®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gymiso®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gymiso®
Study: NCT03487198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole 2-3mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2-3 mg/day